How to Read a ClinicalTrials.gov Listing Without a Medical Degree

Every year, millions of patients and caregivers land on ClinicalTrials.gov looking for a study that might help them. Most leave within minutes. The listings are dense, clinical, and written in a language that assumes you already know what "non-randomized parallel assignment" and "open-label masking" mean. A CISCRP qualitative study of 30 ClinicalTrials.gov listings described the format as dense, text-heavy, and difficult to use, with an outdated design.

The reading level required to parse these pages is part of the problem. Research published in Contemporary Clinical Trials Communications found that ClinicalTrials.gov descriptions contain 65% vocabulary not covered by a basic medical English dictionary, with sentence lengths 65% longer than MedlinePlus consumer health articles. A separate analysis of 798 federally funded trials in eClinicalMedicine found that consent form language averaged a 12th-grade reading level, well above the FDA's recommended 8th grade (Mirza et al., 2024).

The information on these pages is useful, though buried under layers of jargon. What this guide does is pull it to the surface. We'll use a real trial listing as our example, the INSPIRE DUCHENNE gene therapy study (NCT06138639), and walk through every section a patient or caregiver would encounter. By the end, you'll know how to read any listing on the site.

The jargon you'll see on every listing

Before we get into the walkthrough, here's a quick decoder for the terms that show up most often. Bookmark this section and come back to it as needed.

The official title of our example trial reads: **"A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males With Duchenne Muscular Dystrophy."** That sentence packs in 6 distinct pieces of information, and each one tells you something about what participating would actually look like.

Phase 1/2

The study is still in early stages. Phase 1 tests whether a drug is safe. Phase 2 starts measuring whether it works. A combined Phase 1/2 does both at once, typically with a small patient count and close monitoring. If a trial is Phase 1 or 1/2, you're among the first people ever to receive this treatment.

Multicenter

More than one hospital or clinic is running the study. INSPIRE DUCHENNE has 15 sites across the U.S., Canada, Italy, and the U.K.

Open-label

Everyone knows what they're getting. No placebo group, no sugar pill, no guessing. For a parent considering a gene therapy trial for their child, this removes one of the biggest anxieties.

Single intravenous dose

The treatment is given once, through an IV. Some trials require weekly injections for years. This one is a one-time infusion.

In Males

Duchenne muscular dystrophy is an X-linked condition that almost exclusively affects boys. You'll see sex-specific eligibility in many genetic disease trials.

Study design, decoded

Below the title, ClinicalTrials.gov shows a cluster of fields labeled things like "Study Type," "Allocation," "Intervention Model," and "Masking." These look like a form somebody filled out wrong. They're actually describing the study's architecture.

Study Type → Interventional

Participants will receive a treatment. The alternative, "Observational," is where researchers just watch and collect data without giving you anything new. If you're looking for access to a drug, you want Interventional.

Allocation → Non-Randomized

The research team decides which group you're placed in rather than a computer flipping a coin. In INSPIRE DUCHENNE, the groups are based on age, so your child's age determines the cohort. Randomized trials, where a computer assigns groups, are common in Phase 3 studies. Seeing Non-Randomized in a Phase 1/2 trial is normal.

Intervention Model → Parallel

Multiple groups run at the same time. In this trial, 5 age-based cohorts receive SGT-003 simultaneously rather than one after another. The alternative is "Sequential" (each group finishes before the next begins) or "Crossover" (you switch groups partway through).

Masking → None (Open Label)

No blinding. In blinded studies, "Single" means either you or your doctor doesn't know what you're getting. "Double" means neither of you knows. "Quadruple" means the patient, doctor, data analyst, and outcome assessor are all in the dark. Gene therapy trials are rarely blinded because a one-time IV infusion can't be replicated with a placebo saline bag.

What the eligibility criteria are really filtering for

The eligibility section is where most patients get discouraged. It reads like a legal contract crossed with a genetics textbook. The purpose, though, is straightforward. The research team needs a group of participants similar enough to each other that the results can be interpreted clearly. Every criterion exists to control a variable.

INSPIRE DUCHENNE's inclusion criteria start with age ranges for each cohort. These aren't arbitrary. Duchenne progresses differently at different ages, and the researchers need to measure the drug's effect against a predictable disease trajectory.

Cohort 1 (ages 4 to under 7)

Ambulatory. Must complete a 10-meter walk/run in under 30 seconds.

Cohort 2 (ages 7 to under 12)

Ambulatory. Same walk/run requirement.

Cohort 3 (ages 0 to under 4)

Youngest group. Different functional benchmarks.

Cohort 4 (ages 12 to under 18)

Ambulatory. Same walk/run requirement as Cohorts 1 and 2.

Cohort 5 (ages 10 to under 18)

Non-ambulatory patients who were previously able to walk. If your child recently transitioned to a wheelchair, this is the cohort designed for them.

"Negative for AAV antibodies" is a criterion that trips up a lot of gene therapy candidates. AAV (adeno-associated virus) is the delivery vehicle that carries the therapeutic gene into muscle cells. If your child's immune system has already encountered a natural version of this virus, their body might attack the treatment before it can work. Roughly 30 to 60% of the general population has pre-existing AAV antibodies, depending on the serotype, which means a substantial number of otherwise eligible patients will screen out on this one criterion alone.

The steroid requirement is another filter. Cohorts 1, 2, 4, and 5 require a stable daily oral steroid regimen of at least 0.5 mg/kg/day of prednisone or 0.75 mg/kg/day of deflazacort for 12 weeks or more before screening. Steroids are standard of care in DMD, so most families will already meet this. The stability requirement ensures that any improvement seen during the trial can be attributed to the gene therapy rather than a recent steroid dose change.

Endpoints tell you what the trial is actually measuring

This is the section most patients skip, and it's the one that would answer their biggest question. When you join a trial, the researchers are not measuring "did you feel better." They are measuring something precise, and that precise thing determines whether the FDA considers the drug a success.

Primary endpoints (what the FDA cares about most)

Treatment-emergent adverse events through Day 360

They're counting every side effect that shows up in the first year after treatment. For a Phase 1/2 trial, safety is the primary concern.

Microdystrophin protein levels at Day 90

Measured through muscle biopsies. This tells researchers whether the gene therapy is actually producing the protein it was designed to deliver.

Secondary endpoints (does it change daily life?)

North Star Ambulatory Assessment

A 17-item scale scored 0 to 34 measuring how well a child can stand, walk, and climb.

10-meter walk/run velocity

How fast your child can walk or run a short distance.

4-stair climb velocity

Timed stair climbing, a practical measure of leg strength.

6-minute walk test distance

Total distance covered walking for 6 minutes, a standard endurance measure.

Stride velocity (wearable device)

Continuous movement tracking outside the clinic, capturing real-world mobility.

Time to rise from the floor

How long it takes to stand up from lying down, directly tied to daily independence.

“Only 3% of cancer patients enroll in clinical trials despite 76% wanting to if they had the right information.”

CISCRP recruitment statistics

That gap between "protein shows up on a biopsy" and "my child can climb stairs faster" is the central tension in many gene therapy trials. The primary endpoint proves the mechanism works. The secondary endpoints show whether it changes daily life. Both are measured, but the FDA decision often hinges on the primary.

Status fields and what they mean for you right now

Near the top of every listing, you'll see a status label. ClinicalTrials.gov uses a specific vocabulary here, and the differences matter.

Recruiting

The trial is actively enrolling patients. You can contact the research team today. INSPIRE DUCHENNE is currently in this status.

Active, Not Recruiting

The trial is running, but they've already filled their spots. Patients are in it, but new enrollment is closed.

Enrolling by Invitation

Only pre-selected patients can join, usually people who participated in an earlier phase of the same program.

Completed

The study has finished.

Terminated

Stopped early, sometimes for safety reasons, sometimes for business decisions.

Withdrawn

The study was pulled before anyone enrolled.

The dates matter too. INSPIRE DUCHENNE started on May 6, 2024, with an estimated primary completion date of May 2027 and a final completion date of May 2031. Primary completion is when they expect to have the main results. The 2031 date reflects the 5-year follow-up period required for gene therapy studies, since regulators want to know the effects hold up over time.

Finding study locations and the people running them

Scroll to the bottom of any ClinicalTrials.gov listing and you'll find the contacts and locations section. For INSPIRE DUCHENNE, 15 sites are listed across 4 countries. In the U.S., sites include Children's Hospital of Philadelphia, Nationwide Children's Hospital in Columbus, Seattle Children's Hospital, Lurie Children's in Chicago, UCLA, UC Davis, UC San Diego, Oregon Health & Science University, Washington University in St. Louis, Arkansas Children's Hospital, Children's Hospital of the King's Daughters in Norfolk, and Rare Disease Research in Atlanta. International sites include The Hospital for Sick Children in Toronto, Policlinico Gemelli in Rome, and Great Ormond Street Hospital in London.

Each site lists a contact person with a phone number and email. These are typically the research coordinators, not the principal investigators. The PI (principal investigator) is the doctor leading the study at that specific site. INSPIRE DUCHENNE's PI list includes names like Kevin Flanigan at Nationwide Children's, Perry Shieh at UCLA, Francesco Muntoni at Great Ormond Street, and Eugenio Mercuri in Rome. These are physicians you can look up independently to understand their expertise and publication history.

What ClinicalTrials.gov doesn't tell you

Every listing has gaps. ClinicalTrials.gov won't tell you how many of the 60 estimated enrollment slots have already been filled. It won't tell you the travel reimbursement policy. It won't describe the visit schedule, how many times you'll need to come back for assessments, blood draws, and MRIs over 5 years of follow-up. It won't explain whether you'll need to stay near the trial site for days after the infusion for monitoring, or whether the sponsor covers lodging.

For gene therapy trials specifically, the listing won't mention the immunosuppression protocol. Most AAV gene therapies require steroids before and after the infusion to manage the immune response to the viral vector. The duration and intensity of that steroid regimen varies by trial and can significantly affect how your child feels in the weeks following treatment.

These details live in the full protocol document, which is sometimes linked from the listing page but more often isn't. The fastest way to get them is to call the site coordinator listed in the contacts section and ask directly.

Applying this to any listing

We used INSPIRE DUCHENNE as the walkthrough, but the structure is identical across all 400,000+ studies on ClinicalTrials.gov. Every listing has the same fields. The title always packs in the phase, design, and population. The eligibility criteria always serve the same purpose of defining a study group tight enough to produce interpretable results. The endpoints always reveal what the researchers consider success. The status always tells you whether you can act today or whether the window has closed.

If you're looking at a trial for a different condition, Trial Friend translates these listings into plain language automatically. Search by your condition, and the trial pages will break down the same fields covered here, along with side effect data from the FDA, drug mechanism explanations, and study location maps. If a listing still confuses you after reading this guide, ask our chatbot on any Trial Friend page to walk through it with you.